Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology

Publication date: Available online 13 June 2017
Source:Trends in Endocrinology & Metabolism
Author(s): Jo K. Perry, Zheng-Sheng Wu, Hichem C. Mertani, Tao Zhu, Peter E. Lobie
The growth hormone (GH) and insulin-like growth factor-1 (IGF1) axis is the key regulator of longitudinal growth, promoting postnatal bone and muscle growth. The available data suggest that GH expression by tumour cells is associated with the aetiology and progression of various cancers such as endometrial, breast, liver, prostate, and colon cancer. Accordingly there has been increased interest in targeting GH-mediated signal transduction in a therapeutic setting. Because GH has endocrine, autocrine, and paracrine actions, therapeutic strategies will need to take into account systemic and local functions. Activation of related hormone receptors and crosstalk with other signalling pathways are also key considerations.



http://ift.tt/2s6O6YG